Generalized Myasthenia Gravis (gMG) – Market Access and Reimbursement Insights Report – 2025

Generalized Myasthenia Gravis (gMG) Market Access and Reimbursement Insights

Thelansis’s “Generalized Myasthenia Gravis (gMG) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Generalized Myasthenia Gravis (gMG) Overview

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. It arises from autoantibodies—most commonly against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK)—that disrupt normal neuromuscular transmission at the junction between nerves and muscles. Unlike ocular myasthenia, which is limited to eye muscles, gMG affects a broader range of voluntary muscles including those responsible for facial expression, swallowing, speech, limb movement, and respiration. Clinical presentation varies but often includes ptosis, diplopia, dysphagia, dysarthria, and limb weakness, with potential progression to life-threatening respiratory compromise known as myasthenic crisis. Diagnosis typically involves serologic testing for autoantibodies, electrophysiologic studies, and sometimes imaging to assess thymic abnormalities.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Generalized Myasthenia Gravis (gMG) – Market Access and Reimbursement Insights Report – 2025